Life with diabetes usually includes many injections of the blood sugar–controlling hormone insulin. Recent research investigating a once-weekly shot finds it might help lessen the burden a bit for some with the disease.
Two pharmaceutical companies have developed weekly insulin formulations and have tested the drugs in late-stage clinical trials. This September, in the New England Journal of Medicine, researchers reported promising results for efsitora, from Eli Lilly. For adults with type 2 diabetes, the drug worked as well as a once-daily formulation of insulin. But a trial of adults with type 1 diabetes, reported the same month in the Lancet, found there were more episodes of dangerously low
→ Continue reading at Science News